We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+23.31%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$916M
AUM Growth
+$200M
Cap. Flow
+$82.6M
Cap. Flow %
9.02%
Top 10 Hldgs %
26.61%
Holding
112
New
9
Increased
29
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
MNDT
Mandiant, Inc. Common Stock
MNDT
+$17.7M
2
TRN icon
Trinity Industries
TRN
+$17.1M
3
SPLK
Splunk Inc
SPLK
+$9.6M
4
NRG icon
NRG Energy
NRG
+$6.27M
5
XPO icon
XPO
XPO
+$6.11M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$15.5M
2
MDVN
MEDIVATION, INC.
MDVN
+$6.68M
3
AKBA icon
Akebia Therapeutics
AKBA
+$3.68M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$1.92M
5
ARWR icon
Arrowhead Research
ARWR
+$1.69M

Sector Composition

Rank Sector Weight
1 Healthcare 31.22%
2 Technology 16.49%
3 Consumer Discretionary 14.21%
4 Industrials 9.04%
5 Energy 4.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
76
Ultragenyx Pharmaceutical
RARE
$2.56B
$2.31M 0.25%
52,600
– –
SUPN icon
77
Supernus Pharmaceuticals
SUPN
$2.65B
$2.13M 0.23%
257,000
– –
RGEN icon
78
Repligen
RGEN
$7.03B
$1.97M 0.21%
99,400
– –
CSII
79
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.94M 0.21%
64,500
+11,800
+22% +$337K
HPTX
80
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.83M 0.2%
76,300
– –
ADVM
81
DELISTED
Adverum Biotechnologies
ADVM
$1.75M 0.19%
3,240
+1,240
+62% +$478K
WPX
82
DELISTED
WPX Energy, Inc.
WPX
$1.75M 0.19%
+150,000
New +$2.39M
SAAS
83
DELISTED
inContact, Inc.
SAAS
$1.7M 0.19%
193,300
– –
GWPH
84
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.69M 0.18%
25,000
– –
INFI
85
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.69M 0.18%
+100,000
New +$1.46M
ATHN
86
DELISTED
Athenahealth, Inc.
ATHN
$1.62M 0.18%
11,100
– –
TNDM icon
87
Tandem Diabetes Care
TNDM
$1.3B
$1.62M 0.18%
12,725
+4,725
+59% +$655K
SAGE
88
DELISTED
Sage Therapeutics
SAGE
$1.47M 0.16%
40,200
– –
BRKR icon
89
Bruker
BRKR
$9.79B
$1.45M 0.16%
73,900
– –
DRNA
90
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.38M 0.15%
83,700
+20,000
+31% +$231K
INSM icon
91
Insmed
INSM
$22B
$1.37M 0.15%
88,600
– –
SLXP
92
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$1.36M 0.15%
11,800
– –
FEIC
93
DELISTED
FEI COMPANY
FEIC
$1.34M 0.15%
14,800
– –
PCRX icon
94
Pacira BioSciences
PCRX
$1.06B
$1.18M 0.13%
13,300
– –
OMED
95
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1.15M 0.13%
52,800
– –
KPTI icon
96
Karyopharm Therapeutics
KPTI
$159M
$1.12M 0.12%
2,000
– –
RGLS
97
DELISTED
Regulus Therapeutics
RGLS
$962K 0.11%
+500
New +$889K
TLPH icon
98
Talphera
TLPH
$70.1M
$938K 0.1%
6,970
– –
MDSO
99
DELISTED
Medidata Solutions, Inc.
MDSO
$902K 0.1%
18,900
– –
QURE icon
100
uniQure
QURE
$2.93B
$727K 0.08%
49,100
– –
1 2 3
4
5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Eventide Asset Management held 112 positions worth $916M, up 28% from $716M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management deployed $82.6M of net new capital in Q4 2014, opening 9 new positions and adding to 29 existing holdings. Its largest new stake was Mandiant, Inc. Common Stock: 575,600 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 29% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $15.5M trimmed.

  • Eventide Asset Management's largest Q4 2014 buy was Mandiant, Inc. Common Stock: 575,600 shares worth $18.2M.
  • Eventide Asset Management added most to NRG Energy in Q4 2014, an estimated $6.27M increase.
  • Eventide Asset Management's biggest Q4 2014 reduction was Agios Pharmaceuticals, cutting an estimated $15.5M.
  • Eventide Asset Management fully exited Akebia Therapeutics in Q4 2014, selling an estimated $3.68M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $916M portfolio in Q4 2014.
  • Eventide Asset Management opened 9 new positions and closed 6 in Q4 2014.
  • Eventide Asset Management's portfolio value rose 28% quarter-over-quarter to $916M.

Based on Eventide Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.